TScan Therapeutics, Inc.(TCRX)

$0.80—Earnings tomorrow

Chart

TScan Therapeutics, Inc.(TCRX)

NASDAQ

$0.80—Earnings tomorrow

Chart Studio

TCRX(TCRX)

TCRX

Overview Stream Notebook Intel Chart History Fundamentals TTM Earnings Analysts News Financials Segments Insiders Institl.DCF Peers

Q3 2026 EPS Estimate

$-0.29

Aug 11, 2026 · Reports before open

Revenue Estimate

$2M

Analyst Sentiment

Wall St. Consensus

Buy

8 analysts·Limited coverage

Score

7 Buy (88%)1 Hold (13%)0 Sell (-1%)

Rating Breakdown

Strong Buy

00%

Buy

788%

Hold

113%

Sell

00%

Strong Sell

00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Bear

$3.00

+276.8%

Consensus

$7.50

+842.0%

Bull

$12.00

+1407.2%

12-Month Target Range8 analysts

$3.00$7.50$12.00

Current $0.80Consensus

Current Price

$0.80

Upside to Consensus

$6.70

Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Forward Growth Estimates (YoY)

FY2027

Rev-0.73%

EPS—

FY2028

Rev+236.50%

EPS—

FY2029

Rev+86.79%

EPS—

Raw consensus estimates (low / average / high) from covering analysts.

Annual

Metric	FY2026E	FY2027E	FY2028E	FY2029E	FY2030E
Revenue Avg	$8M	$8M	$26M	$49M	$86M
Low	$1M	$7M	$10M	$18M	$31M
High	$13M	$9M	$36M	$68M	$119M
EBITDA Avg	$-8M	$-8M	$-26M	$-49M	$-86M
Low	$-13M	$-9M	$-36M	$-68M	$-119M
High	$-1M	$-7M	$-10M	$-18M	$-31M
EBIT Avg	$-8M	$-8M	$-26M	$-49M	$-86M
Low	$-13M	$-9M	$-36M	$-68M	$-119M
High	$-1M	$-7M	$-10M	$-18M	$-31M
Net Income Avg	$-117M	$-128M	$-126M	$-86M	$-52M
Low	$-213M	$-145M	$-136M	$-128M	$-78M
High	$-105M	$-110M	$-94M	$-15M	$-9M
EPS Avg	$-1.03	$-0.97	$-0.85	$-0.66	$-0.40
Low	$-1.64	$-1.11	$-1.05	$-0.98	$-0.60
High	$-0.81	$-0.85	$-0.72	$-0.11	$-0.07
Analysts (Rev / EPS)	4 / 4	4 / 4	4 / 3	2 / 1	2 / 1

Quarterly

Metric	Q3 2026	Q4 2026	Q1 2027	Q2 2027	Q3 2027	Q4 2027
Revenue Avg	$2M	$2M	$2M	$2M	$2M	$2M
Low	$2M	$2M	$1M	$1M	$1M	$1M
High	$2M	$2M	$2M	$2M	$2M	$2M
EBITDA Avg	$-2M	$-2M	$-2M	$-2M	$-2M	$-2M
Low	$-2M	$-2M	$-2M	$-2M	$-2M	$-2M
High	$-2M	$-2M	$-1M	$-1M	$-1M	$-1M
EBIT Avg	$-2M	$-2M	$-2M	$-2M	$-2M	$-2M
Low	$-2M	$-2M	$-2M	$-2M	$-2M	$-2M
High	$-2M	$-2M	$-1M	$-1M	$-1M	$-1M
Net Income Avg	$-35M	$-32M	$-29M	$-29M	$-30M	$-30M
Low	$-57M	$-36M	$-32M	$-32M	$-33M	$-34M
High	$-26M	$-27M	$-24M	$-25M	$-25M	$-26M
EPS Avg	$-0.27	$-0.25	$-0.22	$-0.22	$-0.23	$-0.23
Low	$-0.44	$-0.27	$-0.24	$-0.25	$-0.25	$-0.26
High	$-0.20	$-0.21	$-0.19	$-0.19	$-0.20	$-0.20
Analysts (Rev / EPS)	2 / 4	1 / 1	1 / 1	1 / 1	1 / 1	1 / 1

Earnings Surprises

Recent Analyst Actions

Mar 7, 2025Barclays

TScan Therapeutics price target lowered to $3 from $14 at Barclays

Target:$3.00

+51.5%from $1.98

May 16, 2024BTIG

TScan Therapeutics initiated with a Buy at BTIG

Target:$12.00

+34.4%from $8.93

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance